Developing a unique mRNA platform

Combined Therapeutics is an emerging mRNA medicines company developing a unique modified mRNA platform to protect vulnerable populations from global infectious diseases as well as to cure cancer.

Fueled by our proprietary technologies, which target protein expression to specific tissues while reducing off target effects, combined with an experienced team in delivery and mRNA-based therapeutics, we are committed to harnessing the body’s machinery to protect and improve patients’ lives.

 

About Us

Combined Therapeutics has developed a unique platform built around Multi Organ Protective (MOP) miRNA sequences combined to therapeutic mRNAs, that allow to target and focus therapeutic protein expression in specific tissues, spare healthy tissues and reduce off target effects.

Together with our partners, we are committed to using our platform to protect vulnerable populations from global infectious disease threats as well as to cure cancer.

Board of Directors

Board Director

Mr. Matussiere has worked until 2017 and for more than twenty years as an investment banker for Société Générale, Citigroup and BNP Paribas, primarily out of London. His focus was on the sales and marketing of structured products, mainly in the credit space. Since 2017, Pierre has become an active Angel investor and fundraiser -through his FCA regulated company M Finance- focusing on sectors such as hospitality, leasing of transport equipment, Healthtech, residential and commercial properties and Biotech. Pierre graduated in 1995 from HEC in Paris.


President and Cofounder CEO, Board Director

Dr. Micol has been President and co-founder CEO of Combined Therapeutics since 2016. Previously, he held several positions across the Institut Mérieux group: ABlinc (USA), Shantha Biotechnics (India), Transgene (China and France). Dr. Micol is an entrepreneur with affiliations to six famous universities (MIT in US, LSE in UK, Paris VI, Paris V, Paris Dauphine in France and Global LBS in UK). Additionally he helped to set up the first reference center for primary immunodeficiency in France in 2005.


Board Director
Dr. VanCott is the Chief Technology & Strategy Officer for Catalent Cell & Gene Therapy, a CDMO manufacturing viral vectors for gene and cell therapies based in the US and Europe. He is responsible for strategically enhancing and augmenting CMC services to meet the market demand of increasingly complex cell and gene therapy products. He also leads the product development and internal R&D teams. Prior to this, he was the CEO for 10 years at another Maryland-based CMO/CRO (ABL) where he was responsible for the strategic international growth of the company. He has been involved in virus and biologic product development for over 25 years. He has a PhD in physical chemistry and started his career as a Captain in the US Army stationed at Walter Reed Army Institute of Research (WRAIR) studying and developing HIV vaccines for international deployment from initial construction through preclinical development and GMP manufacturing to clinical trials.


Board Director
Dr. Paul K. Wotton is the Chief Executive Officer at Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Dr Wotton has over 30 years of experience in scientific research, product development and corporate growth in the life science industry. Previously, he served as Founding President and Chief Executive Officer of Sigilon Therapeutics, Inc. Prior to Sigilon, Dr. Wotton served as President and Chief Executive Officer of Ocata Therapeutics until its acquisition by Astellas Pharma where he was also Co-Chairman of the Office of Integration. In previous roles, he has served as President and Chief Executive Officer of Antares Pharma (NASDAQ:ATRS) as well as Chief Executive Officer of Topigen Pharmaceuticals. Dr. Wotton is a named inventor on numerous patents and was the Ernst & Young Entrepreneur of the Year Regional (NJ) Winner Life Sciences in 2014. He serves on the Boards of Directors of Vericel Corporation (NASDAQ: VCEL) and Cynata Therapeutics (ASX: CYP) as its Chairman. Until recently Paul was a board member at Veloxis Pharmaceuticals A/S (Copenhagen: VELO) which was recently acquired by Asahi. Dr. Wotton holds a B.Pharm (Honors) from UCL, London’s global university, and a Ph.D. in Pharmaceutical Sciences from University of Nottingham.

 

Operational Team

Romain Micol MD, MPH, PhD, MBA, LLM

President and CEO (cofounder), Leadership

Raffy Kazandjian, MBA

CTx SAS Managing Director, Leadership

Valérie Duval, PhD

Associate Director, Biology

Pallab Ghosh

Principal Scientist, Biology

Teddy Jégu, PhD

Project Manager, Biology

Kim Foster, MLS(ASCP)CM

Senior Research Associate, Biology

Lauren Speciner, PhD

Principal Scientist, Formulation & Process Development

Asad Khanmohammed

Senior Research Associate, Formulation & Process Development

Pierre Vochel

Senior Manager Strategy & Finance, Finance & Strategy

Paul Waldron, PhD

Patent Assistant, IP & Corporate Attorney

Advisors / Consultants

Thomas VanCott, PhD

Business Development

Mark Tracy, PhD

Platform Development

Devenand Crease, PhD

Patent Attorney

Sarah Cooleybeck, J.D.

Corporate Attorney

Robert Birnbaum

General Secretary

Robert Langer, ScD

Cofounder – Oncology / Virotherapy

Dan Anderson, PhD

Cofounder – Oncology / Virotherapy

David Neafus, MBA

Financial Advisor

Ronald E. Kaunfer, BSc

Accounting Director

Edouard Hervey

Corporate Strategy

EXISTING Science LANDSCAPE

What are mRNA therapies

  • Utilizes existing cell machinery to make therapeutic proteins that can treat disease
  • Can be modified to produce therapeutic proteins only in the target cells, such as tumoral cells, and spare healthy tissue.
  • Nucleic acids therapies are a very versatile platform as they can code for any protein of interest and are transient; broken down quickly after their job is done.

Our mRNA platform: Combined Therapeutics’ Drug and Modulation Platform (DMPCTx):

  • A new generation of modified mRNA delivered in a lipid nanoparticle capable of targeted protein expression in specific tissues
  • 3 routes of Administration: Intravenous, Intra-tumoral, Intramuscular
  • 2 medical applications: Vaccines & Oncology
  • Multi-Organ Protection (MOP): Treatment side effects occur when healthy cells are affected alongside diseased cells. MOP is key to delivering and focusing treatment to diseased cells only, thus preventing off target effects

Infectious disease – Prophylactic vaccine

  • The success of mRNA vaccines in the global fight against COVID19 highlights the potential of this new class of medicines. RNA vaccines can be developed more rapidly than traditional vaccines to tackle infectious disease outbreaks and can be leveraged to direct the immune system more effectively against infectious diseases.
  • We can use our unique approach to develop next generation vaccines. Our infectious disease vaccine candidates contain modified mRNA-encoding antigens to specifically activate an immune response, allowing the body to fend off future infections. At Combined Therapeutics we can deliver multiple mRNAs that encode for both an antigen and an immunomodulator. This dual approach boosts the immune response against the infection, leading to better disease protection

Oncology

  • Immunotherapy is a promising approach that bolsters the patient immune system to fight his own cancer. However, it can generate severe adverse effects and exhibits a low response rate, particularly in solid cancers with an immunosuppressive microenvironment.
  • DMPCTx revolutionizes the treatment of solid tumors:
  • Protect: Following a systemic administration of mRNA-based immunotherapy, DMPCTx safely produces therapeutic proteins in tumor cells only, fully sparing healthy tissues, reducing systemic toxicities and preserving safety
  • Sensitize & Boost: DMPCTx platform can be harnessed as a companion boost to sensitize all tumors to any immunotherapeutic regimen, such as virotherapy, CAR T-cell therapy, and immune checkpoint inhibitors, and thus significantly enhance their efficacies

Use our solution to enhance your immunotherapy or Vaccine applications

News

3/14/22 – 3/16/22
Combined Therapeutics is invited to attend Pierre Fabre Virtual Biopharma Partnering in March 2022 to showcase the company and our innovative therapeutics.

1/7/22
CTx has entered in a lease to build its own laboratory in Cambridge.

1/5/22
Edouard Hervey, former Goldman Sachs partner, who has become a special advisor to the CEO with a core focus on corporate strategy

12/15/21
Pallab Ghosh joins Combined Therapeutics as a Principal Scientist.

4/5/21
Paul Waldron joins Combined Therapeutics as Patent Assistant.

2/1/21
Teddy Jégu joins Combined Therapeutics as Project Manager.

1/25/21
Kim Foster joins Combined Therapeutics as Research Associate.